Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06312020 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

A Phase 2 study of Sjogren's Syndrome, sponsored by Amgen.

Active
Registry status
Phase 2
Development phase
209
Enrollment target
20
Study locations

NCT06312020: Active Phase 2 study of Sjogren's Syndrome, sponsored by Amgen.

NCT06312020 is a Phase 2 study of Sjogren's Syndrome that is active but no longer recruiting, run by Amgen. The registered enrollment target is 209 participants, below the 278-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06312020, a Phase 2 study of Sjogren's Syndrome, is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
209 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG HZN-1116

Study Locations (20)

Florida

  • Life Arc Research Centers Corp - Miami
  • IRIS Research and Development LLC - Plantation
  • Clinical Research of West Florida Inc - Tampa - Tampa

Texas

  • Tekton Research, LLC - W Gate Blvd - Austin - PPDS - Austin
  • Prolato Clinical Research Center - Houston
  • R & H Clinical Research-777 S Fry Rd - Katy

Ciudad Autónoma de BuenosAires

  • DOM Centro de Reumatología - Buenos Aires
  • Expertia S.A- Mautalén Salud e Investigación - Buenos Aires
  • Centro Privado de Medicina Familiar - Buenos Aires

Arizona

  • Arizona Arthritis & Rheumatology Research-S Vineyard Ave - Mesa
  • Arizona Arthritis and Rheumatology Associates -4550 E Bell Rd - Phoenix

California

  • Neurovations Research - Napa

Georgia

  • Augusta University Medical Center-Augusta-1120 15th St - Augusta

Massachusetts

  • Tufts Medical Center - 800 Washington St - PPDS - Boston

New York

  • Pioneer Clinical Research NY - New York

Trial Details

FieldValue
Enrollment Target 209 participants
Start Date 2024-05-09
Est. Completion 2026-11-24
Phase Phase 2
Amgen

558 total trials

What the registry record for NCT06312020 still lists

NCT06312020 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 278-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (25% lower).

The record links to 1 condition, with Sjogren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06312020 names 20 study sites across 13 states, led by Florida, Texas, Ciudad Autónoma de BuenosAires.

Frequently Asked Questions

What is clinical trial NCT06312020 about?

NCT06312020 is a clinical study titled "A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome". The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

What is the current status of trial NCT06312020?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2024-05-09. Estimated completion is 2026-11-24.

What conditions does trial NCT06312020 study?

This clinical trial studies the following conditions: Sjogren's Syndrome.

What interventions are being tested in trial NCT06312020?

The interventions under investigation include: Placebo (DRUG), HZN-1116 (DRUG).

Who is sponsoring clinical trial NCT06312020?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06312020 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sjogren's Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06312020's enrollment target sits among peer trials

209 8th of 20 higher than 13 of 20 other Sjogren's Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sjogren's Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04742634 · 209 participants · Phase 1

    Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

  • NCT07214688 · 209 participants · Phase 2

    Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06312020, the US trial registry maintained by the National Library of Medicine. NCT06312020 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.